<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530920</url>
  </required_header>
  <id_info>
    <org_study_id>1182.107</org_study_id>
    <nct_id>NCT00530920</nct_id>
  </id_info>
  <brief_title>Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients</brief_title>
  <official_title>A Multicenter, Randomized, Open Label, Clinical Trial to Evaluate Three Doses of Tipranavir Boosted With Ritonavir (500 mg/200 mg qd, 250 mg/100 mg Bid and 500 mg/100 mg Bid) by Assessing the Steady-state Pharmacokinetics and Short-term Efficacy and Safety in HIV-1 Positive Treatment naïve Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV)
      and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be
      used in pivotal trial by assessing the steady-state pharmacokinetics and short-term efficacy
      and safety
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Viral Load (log10 Copies/mL) Change From Baseline (Last Observation Carried Forward (LOCF))</measure>
    <time_frame>Baseline (Day 0) to Final (Day 14)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance I(Cl/F) of Tipranavir</measure>
    <time_frame>Final (Day 14)</time_frame>
    <description>Tipranavir pharmacokinetics - Clearance (CL) is defined as the dose of a drug divided by the area-under-the-concentration-time curve (AUC), ie. CL = Dose / AUC. For extravascu-lar models the fraction of dose absorbed cannot be estimated, therefore &quot;clear-ance&quot; for these models is actually Cl/F where F is the fraction of the drug dose which is absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve(AUC) of Tipranavir 24 h for Once Daily (QD) and AUC 12 h for Twice Daily (BID)</measure>
    <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
    <description>Tipranavir (TPV) pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration-24 Hour (hr) Post Dose of Tipranavir - (Cp 24 h for QD and 12 hr Post Dose (CP 12h) for BID</measure>
    <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
    <description>TPV pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration (Cmin) of Tipranavir</measure>
    <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
    <description>TPV pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of Tipranavir</measure>
    <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
    <description>TPV pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (V/F) of Tipranavir</measure>
    <time_frame>Final (Day 14)</time_frame>
    <description>Tipranavir pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-Life (t1/2) of Tipranavir</measure>
    <time_frame>Final (Day 14)</time_frame>
    <description>Tipranavir pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of Tipranavir</measure>
    <time_frame>Final (Day 14)</time_frame>
    <description>Tipranavir pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 24 of Ritonavir for QD and AUC 12 of Ritonavir for BID</measure>
    <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
    <description>Ritonavir pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cp 24 h of Ritonavir for QD and CP 12 h of Ritonavir for BID</measure>
    <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
    <description>Ritonavir pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance I(Cl/F) of Ritonavir</measure>
    <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
    <description>Ritonavir pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (V/F) of Ritonavir</measure>
    <time_frame>Final (Day 14)</time_frame>
    <description>Ritonavir pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-Life (t1/2) of Ritonavir</measure>
    <time_frame>Final (Day 14)</time_frame>
    <description>Ritonavir pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Ritonavir</measure>
    <time_frame>Final (Day 14)</time_frame>
    <description>Ritonavir pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Ritonavir</measure>
    <time_frame>Visits baseline, 5, 7, 9 and 13 or 14</time_frame>
    <description>Ritonavir pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Abnormal Findings in Laboratory and Physical Examination</measure>
    <time_frame>Screening through the end of the study (14 days)</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">85</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipranavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent in accordance with GCP and local regulatory requirements prior
             to trial participation.

          -  HIV-1 infected men and non-pregnant women who are treatment naïve, with positive
             serology (EIA) confirmed by Western blot.

          -  Age &gt; 18 and &lt; 65 years.

          -  CD4 &gt; 200 cells/mm3

          -  Viral load (HIV-1 mRNA viral load) &gt; 5,000 copies/mL.

          -  Ability to swallow multiple large capsules without difficulty.

          -  Acceptable laboratory values that indicate adequate baseline organ function at
             screening visit.

          -  Laboratory values are considered to be acceptable if the severity of any parameter is
             = &lt; Grade 2, based on the DAIDS/ACTG Grading Scale (see Appendix 10.2).

          -  Acceptable medical history, physical examination, and 12-lead ECG at screening

          -  Willingness to abstain from the following starting 2 weeks prior to administration of
             any study medication and up until the end of the study:

             o Grapefruit or grapefruit juice, Seville oranges, St. John's Wort, and Milk Thistle.

          -  Willingness to abstain from alcohol 3 days prior to administration of any study
             medication up to the end of the study.

          -  Willingness to abstain from the following starting 3 days prior to PK sampling:

             o Garlic supplements and methylxanthine containing foods or drinks (including coffee,
             tea, cola, energy drinks, chocolate, etc.).

          -  Willingness to abstain from over-the-counter herbal medications for the duration of
             the study.

          -  Willingness to abstain from any over the counter medication 7 days prior to
             administration of any study medication (including vitamins, minerals, dietary
             supplements and antacids) during the study until completion of the post study
             assessments.

        Exclusion Criteria:

          -  Female patients of reproductive potential who:

               -  Have positive serum pregnancy test.

               -  Have not been using a barrier method of contraception for at least 3 months prior
                  to participation in the study.

               -  Are not willing to use a reliable method of barrier contraception (such as
                  diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during
                  and 60 days after completion/termination of the trial.

               -  Are breast-feeding.

          -  Suspected or documented seroconversion within last 6 months

          -  Participation in another trial with an investigational medicine within 2 months prior
             to Day 0 of this study.

          -  Use of any pharmacological contraceptive (including oral, patch or injectable
             contraceptives) within 1 month prior to Day 0 and for the duration of the study.

          -  Use of hormone replacement therapy within 1 month prior to Day 0 and anytime during
             the study.

          -  History of acute illness within 30 days prior to Day 0.

          -  Have evidence of active or acute HBV or HCV.

          -  Alcohol or substance abuse within 1 year prior to screening or during the study.

          -  Patients with a history of any illness or allergy that, in the opinion of the
             investigator, might confound the results of the study or pose additional risk in
             administering TPV.

          -  Patients who have taken (within 7 days prior to Day 0) any over-the-counter or
             prescription medication that, in the opinion of the investigator in consultation with
             the BI clinical monitor, might interfere with absorption, distribution, or metabolism
             of the study medications.

          -  Known hypersensitivity to any ingredients of the test drug.

          -  Inability to adhere to the protocol.

          -  Genotypic resistance to tipranavir (defined as a TPV mutation score &gt; 4).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1182.107.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.107.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.107.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.107.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.107.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antella (fi)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.107.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.107.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.107.39011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.107.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.107.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.107.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.107.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2007</study_first_submitted>
  <study_first_submitted_qc>September 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2007</study_first_posted>
  <results_first_submitted>May 15, 2009</results_first_submitted>
  <results_first_submitted_qc>May 15, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2009</results_first_posted>
  <last_update_submitted>May 27, 2014</last_update_submitted>
  <last_update_submitted_qc>May 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
          <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
        </group>
        <group group_id="P2">
          <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
          <description>Tipranavir 250 mg boosted with ritonavir 100 mg given once daily</description>
        </group>
        <group group_id="P3">
          <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
          <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
          <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
        </group>
        <group group_id="B2">
          <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
          <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
        </group>
        <group group_id="B3">
          <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
          <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="7.54"/>
                    <measurement group_id="B2" value="36.9" spread="8.04"/>
                    <measurement group_id="B3" value="36.4" spread="8"/>
                    <measurement group_id="B4" value="35.3" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Viral Load (log10 Copies/mL) Change From Baseline (Last Observation Carried Forward (LOCF))</title>
        <time_frame>Baseline (Day 0) to Final (Day 14)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load (log10 Copies/mL) Change From Baseline (Last Observation Carried Forward (LOCF))</title>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>Log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" lower_limit="-1.66" upper_limit="-1.24"/>
                    <measurement group_id="O2" value="-1.55" lower_limit="-1.70" upper_limit="-1.37"/>
                    <measurement group_id="O3" value="-1.47" lower_limit="-1.66" upper_limit="-1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>NULL HYPOTHESIS (H0): Median viral load reduction from baseline &gt;1.2 log10 copies/mL within each group</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.997</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.43</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NULL HYPOTHESIS (H0): Median viral load reduction from baseline &gt;1.2 log10 copies/mL within each group</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.55</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>NULL HYPOTHESIS (H0): Median viral load reduction from baseline &gt;1.2 log10 copies/mL within each group</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.998</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.47</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Clearance I(Cl/F) of Tipranavir</title>
        <description>Tipranavir pharmacokinetics - Clearance (CL) is defined as the dose of a drug divided by the area-under-the-concentration-time curve (AUC), ie. CL = Dose / AUC. For extravascu­lar models the fraction of dose absorbed cannot be estimated, therefore &quot;clear­ance&quot; for these models is actually Cl/F where F is the fraction of the drug dose which is absorbed.</description>
        <time_frame>Final (Day 14)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance I(Cl/F) of Tipranavir</title>
          <description>Tipranavir pharmacokinetics - Clearance (CL) is defined as the dose of a drug divided by the area-under-the-concentration-time curve (AUC), ie. CL = Dose / AUC. For extravascu­lar models the fraction of dose absorbed cannot be estimated, therefore &quot;clear­ance&quot; for these models is actually Cl/F where F is the fraction of the drug dose which is absorbed.</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="26.79"/>
                    <measurement group_id="O2" value="1.43" spread="26.77"/>
                    <measurement group_id="O3" value="1.57" spread="35.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve(AUC) of Tipranavir 24 h for Once Daily (QD) and AUC 12 h for Twice Daily (BID)</title>
        <description>Tipranavir (TPV) pharmacokinetics</description>
        <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve(AUC) of Tipranavir 24 h for Once Daily (QD) and AUC 12 h for Twice Daily (BID)</title>
          <description>Tipranavir (TPV) pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>h*uM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="571.3" spread="27.3"/>
                    <measurement group_id="O2" value="289.3" spread="26.8"/>
                    <measurement group_id="O3" value="538.2" spread="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration-24 Hour (hr) Post Dose of Tipranavir - (Cp 24 h for QD and 12 hr Post Dose (CP 12h) for BID</title>
        <description>TPV pharmacokinetics</description>
        <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration-24 Hour (hr) Post Dose of Tipranavir - (Cp 24 h for QD and 12 hr Post Dose (CP 12h) for BID</title>
          <description>TPV pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>uM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="92.4"/>
                    <measurement group_id="O2" value="10.27" spread="49.4"/>
                    <measurement group_id="O3" value="17.75" spread="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Concentration (Cmin) of Tipranavir</title>
        <description>TPV pharmacokinetics</description>
        <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Concentration (Cmin) of Tipranavir</title>
          <description>TPV pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>uM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="106.8"/>
                    <measurement group_id="O2" value="12.73" spread="53.1"/>
                    <measurement group_id="O3" value="21.26" spread="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) of Tipranavir</title>
        <description>TPV pharmacokinetics</description>
        <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Tipranavir</title>
          <description>TPV pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>uM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.64" spread="20.2"/>
                    <measurement group_id="O2" value="36.98" spread="19.9"/>
                    <measurement group_id="O3" value="69.66" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (V/F) of Tipranavir</title>
        <description>Tipranavir pharmacokinetics</description>
        <time_frame>Final (Day 14)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (V/F) of Tipranavir</title>
          <description>Tipranavir pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.02" spread="14.33"/>
                    <measurement group_id="O2" value="9.33" spread="9.17"/>
                    <measurement group_id="O3" value="9.39" spread="12.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-Life (t1/2) of Tipranavir</title>
        <description>Tipranavir pharmacokinetics</description>
        <time_frame>Final (Day 14)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-Life (t1/2) of Tipranavir</title>
          <description>Tipranavir pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="26.3"/>
                    <measurement group_id="O2" value="4.51" spread="22.4"/>
                    <measurement group_id="O3" value="4.14" spread="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cmax (Tmax) of Tipranavir</title>
        <description>Tipranavir pharmacokinetics</description>
        <time_frame>Final (Day 14)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) of Tipranavir</title>
          <description>Tipranavir pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.07" spread="14.7"/>
                    <measurement group_id="O2" value="2.34" spread="15.2"/>
                    <measurement group_id="O3" value="2.38" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 24 of Ritonavir for QD and AUC 12 of Ritonavir for BID</title>
        <description>Ritonavir pharmacokinetics</description>
        <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 24 of Ritonavir for QD and AUC 12 of Ritonavir for BID</title>
          <description>Ritonavir pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>h*uM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" spread="44.0"/>
                    <measurement group_id="O2" value="2.25" spread="47.0"/>
                    <measurement group_id="O3" value="1.74" spread="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cp 24 h of Ritonavir for QD and CP 12 h of Ritonavir for BID</title>
        <description>Ritonavir pharmacokinetics</description>
        <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cp 24 h of Ritonavir for QD and CP 12 h of Ritonavir for BID</title>
          <description>Ritonavir pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>uM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="206.2"/>
                    <measurement group_id="O2" value="0.039" spread="134.0"/>
                    <measurement group_id="O3" value="0.025" spread="129.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Clearance I(Cl/F) of Ritonavir</title>
        <description>Ritonavir pharmacokinetics</description>
        <time_frame>Final (Day 13 for QD, Day 14 for BID)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance I(Cl/F) of Ritonavir</title>
          <description>Ritonavir pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" spread="44.0"/>
                    <measurement group_id="O2" value="44.4" spread="47.0"/>
                    <measurement group_id="O3" value="57.4" spread="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (V/F) of Ritonavir</title>
        <description>Ritonavir pharmacokinetics</description>
        <time_frame>Final (Day 14)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (V/F) of Ritonavir</title>
          <description>Ritonavir pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" spread="26.8"/>
                    <measurement group_id="O2" value="90.8" spread="24.7"/>
                    <measurement group_id="O3" value="88.9" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-Life (t1/2) of Ritonavir</title>
        <description>Ritonavir pharmacokinetics</description>
        <time_frame>Final (Day 14)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-Life (t1/2) of Ritonavir</title>
          <description>Ritonavir pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="45.5"/>
                    <measurement group_id="O2" value="1.42" spread="59.5"/>
                    <measurement group_id="O3" value="1.07" spread="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of Ritonavir</title>
        <description>Ritonavir pharmacokinetics</description>
        <time_frame>Final (Day 14)</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Ritonavir</title>
          <description>Ritonavir pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="23.9"/>
                    <measurement group_id="O2" value="2.33" spread="24.9"/>
                    <measurement group_id="O3" value="2.05" spread="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Ritonavir</title>
        <description>Ritonavir pharmacokinetics</description>
        <time_frame>Visits baseline, 5, 7, 9 and 13 or 14</time_frame>
        <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Ritonavir</title>
          <description>Ritonavir pharmacokinetics</description>
          <population>Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment</population>
          <units>uM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.632" spread="32.5"/>
                    <measurement group_id="O2" value="0.346" spread="30.7"/>
                    <measurement group_id="O3" value="0.291" spread="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Abnormal Findings in Laboratory and Physical Examination</title>
        <time_frame>Screening through the end of the study (14 days)</time_frame>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O2">
            <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
          </group>
          <group group_id="O3">
            <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
            <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Abnormal Findings in Laboratory and Physical Examination</title>
          <population>Treated set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase (ALT) increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase (AST) increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days, from first treatment until last treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily</title>
          <description>Tipranavir 500 mg boosted with ritonavir 200 mg given once daily</description>
        </group>
        <group group_id="E2">
          <title>Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily</title>
          <description>Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily</description>
        </group>
        <group group_id="E3">
          <title>Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily</title>
          <description>Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increaset</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Pharmaceuticals</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

